Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis.

Cardiovascular disease is increased in patients with chronic kidney disease (CKD) and is the principle cause of morbidity and mortality in these patients. In patients with stage 5 CKD, structural changes in the myocardium have been implicated as the principle cardiovascular processes leading to this increase in morbidity and mortality, while atherosclerotic events including acute myocardial infarction and strokes are responsible for approximately 10-15% of cardiovascular deaths. Dyslipidemia is common in CKD patients and is usually not characterized by elevated cholesterol levels, except in patients with marked proteinuria. Increased triglyceride levels in conjunction with decreased high-density lipoprotein levels are the commonest qualitative abnormality. Characteristically, abnormalities in the metabolism of apolipoprotein (apo) B-containing lipoproteins have been described, including both gut derived (apoB-48) as well as those produced by hepatic synthesis (apoB-100). A decrease in enzymatic delipidation as well as reduced receptor removal of these lipoproteins both contribute to the increased levels of these apo-B-containing particles and their remnants (which are believed to be highly atherogenic). Abnormalities in the metabolism of apoA-containing lipoproteins are also present and these changes contribute to the lower levels of HDL seen. Qualitative abnormalities of these HDL particles may be associated with cellular oxidative injury and contribute to a pro-inflammatory, pro-thrombotic milieu that is frequently present in CKD patients.

[1]  Huiliang Xie,et al.  Fibroblast growth factor 23 and Inflammation in CKD. , 2012, American Society of Nephrology. Clinical Journal.

[2]  W. Hörl,et al.  Serum amyloid A in uremic HDL promotes inflammation. , 2012, Journal of the American Society of Nephrology : JASN.

[3]  H. Rodbard,et al.  American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[4]  H. Rodbard,et al.  American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[5]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[6]  M. Budoff,et al.  Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Bertram L Kasiske,et al.  The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. , 2011, Kidney international.

[8]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[9]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[10]  S. Yusuf,et al.  Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. , 2011, Kidney international.

[11]  K. Iseki,et al.  Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[12]  Keith C. Norris,et al.  Lipid Disorders and Their Relevance to Outcomes in Chronic Kidney Disease , 2011, Blood Purification.

[13]  J. Tomassini,et al.  Lipid abnormalities in patients with chronic kidney disease. , 2011, Contributions to nephrology.

[14]  N. Vaziri Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. , 2010, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[15]  M. Sarnak,et al.  Cardiovascular disease and CKD: core curriculum 2010. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[17]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[18]  D. Bolignano,et al.  Alterations of Lipid Metabolism in Chronic Nephropathies: Mechanisms, Diagnosis and Treatment , 2010, Kidney and Blood Pressure Research.

[19]  P. McCullough,et al.  Cardiorenal Interaction: Appropriate Treatment of Cardiovascular Risk Factors to Improve Outcomes in Chronic Kidney Disease , 2010, Postgraduate medicine.

[20]  D. Fliser,et al.  Endothelial progenitor cells in chronic kidney disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  G. Watts,et al.  Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III , 2009, Journal of Lipid Research.

[22]  Satoko Nakamura,et al.  Coronary calcification in patients with chronic kidney disease and coronary artery disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[23]  M. Bouchenak,et al.  Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure patients , 2009, BMC cardiovascular disorders.

[24]  H. Moradi,et al.  In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. , 2009, Kidney international.

[25]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[26]  T. Olivecrona,et al.  PROGRESS IN UREMIC TOXIN RESEARCH: Lipoprotein Lipase Disturbances Induced by Uremia and Hemodialysis , 2009, Seminars in dialysis.

[27]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[28]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[29]  Josef Coresh,et al.  Conceptual model of CKD: applications and implications. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  H. Moradi,et al.  Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. , 2009, Translational research : the journal of laboratory and clinical medicine.

[31]  G. Kaysen New Insights into Lipid Metabolism in Chronic Kidney Disease: What Are the Practical Implications? , 2009, Blood Purification.

[32]  G. Kaysen Lipid and lipoprotein metabolism in chronic kidney disease. , 2009, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[33]  Rinaldo Bellomo,et al.  Cardiorenal syndrome. , 2008, Journal of the American College of Cardiology.

[34]  M. Adachi,et al.  Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. , 2008, Atherosclerosis.

[35]  G. Watts,et al.  Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. , 2008, Atherosclerosis.

[36]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[37]  J. Pais de Barros,et al.  Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase. , 2007, Kidney international.

[38]  F. Kronenberg,et al.  In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. , 2007, Kidney international.

[39]  Kdoqi KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  M. Sarnak,et al.  Managing dyslipidemia in chronic kidney disease , 2004, Journal of General Internal Medicine.

[41]  T. V. van Berkel,et al.  Emerging roles of the intestine in control of cholesterol metabolism. , 2006, World journal of gastroenterology.

[42]  S. Reddy,et al.  Mechanisms of Disease: proatherogenic HDL—an evolving field , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[43]  G. Shearer,et al.  Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion. , 2006, Kidney international.

[44]  Kdoqi Disclaimer,et al.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  C. Furberg,et al.  Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? , 2006, The American journal of cardiology.

[46]  N. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. , 2006, American journal of physiology. Renal physiology.

[47]  H. Moradi,et al.  Mechanisms of dyslipidemia of chronic renal failure , 2006, Hemodialysis international. International Symposium on Home Hemodialysis.

[48]  F. Kronenberg,et al.  Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[49]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[50]  T. Olivecrona,et al.  A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  N. Powe,et al.  High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[52]  N. Vaziri,et al.  Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. , 2005, Kidney international.

[53]  G. Dagenais,et al.  Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Québec Cardiovascular Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[54]  A. Folsom,et al.  Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. , 2005, Journal of the American Society of Nephrology : JASN.

[55]  A. Murray,et al.  Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. , 2005, Journal of the American Society of Nephrology : JASN.

[56]  P. McCullough Cardiovascular disease in chronic kidney disease from a cardiologist's perspective , 2004, Current opinion in nephrology and hypertension.

[57]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[58]  Shirin Rahmani,et al.  Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.

[59]  N. Vaziri,et al.  Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. , 2003, Kidney international.

[60]  M. Ageta,et al.  Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction. , 2003, Journal of atherosclerosis and thrombosis.

[61]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.

[62]  J. Dietschy,et al.  Sterol absorption by the small intestine , 2003, Current opinion in lipidology.

[63]  B. Kasiske,et al.  K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease , 2003 .

[64]  B. Psaty,et al.  Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency , 2003, Circulation.

[65]  Xavier Collet,et al.  Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis , 2003, Nature.

[66]  T. Olivecrona,et al.  Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients , 2003, Scandinavian journal of clinical and laboratory investigation.

[67]  B. Kasiske,et al.  K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease , 2003 .

[68]  P. Stenvinkel,et al.  Review Articles: Inflammation in End‐stage Renal Disease: Sources, Consequences, and Therapy , 2002, Seminars in dialysis.

[69]  C. Wanner,et al.  Inflammation and cardiovascular risk in dialysis patients. , 2002, Kidney international. Supplement.

[70]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[71]  J. Solski,et al.  apoA- AND apoB-CONTAINING LIPOPROTEINS AND Lp(A) CONCENTRATION IN NON-DIALYZED PATIENTS WITH CHRONIC RENAL FAILURE , 2002, Renal failure.

[72]  B. Kasiske EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE AFTER RENAL TRANSPLANTATION , 2001, Transplantation.

[73]  C. Packard,et al.  The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria. , 2001, Atherosclerosis.

[74]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[75]  F. Kronenberg,et al.  Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. , 2000, Journal of the American Society of Nephrology : JASN.

[76]  I. Lemieux,et al.  The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. , 1999, Diabetes & metabolism.

[77]  N. Vaziri,et al.  Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[78]  A. Collins,et al.  Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. , 1998, The New England journal of medicine.

[79]  T. Rabelink,et al.  Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.

[80]  N. Vaziri,et al.  Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. , 1998, Kidney international.

[81]  N. Vaziri,et al.  Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. , 1997, American journal of physiology. Renal physiology.

[82]  N. Vaziri,et al.  Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[83]  N. Vaziri,et al.  Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. , 1997, Kidney international.

[84]  N. Vaziri,et al.  Down-regulation of VLDL receptor expression in chronic experimental renal failure. , 1997, Kidney international.

[85]  B. Kasiske,et al.  Cardiovascular disease after renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[86]  N. Vaziri,et al.  Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. , 1996, Kidney international.

[87]  N. Vaziri,et al.  Down-regulation of hepatic LDL receptor expression in experimental nephrosis. , 1996, Kidney international.

[88]  Y. Marcel,et al.  Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. , 1996, Biochemistry.

[89]  S. Massry,et al.  Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. , 1996, The Journal of clinical investigation.

[90]  N. Vaziri,et al.  Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. , 1995, Kidney international.

[91]  P. Wilson,et al.  Lipoprotein(a) and coronary heart disease. , 1994, Chemistry and physics of lipids.

[92]  O. Samuelsson,et al.  Lipoprotein metabolism and renal failure. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[93]  Y. Kawarabayasi,et al.  Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[94]  S. Massry,et al.  Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. , 1990, Kidney international.

[95]  A. Damião,et al.  [Chylomicron metabolism]. , 1989, Revista do Hospital das Clinicas.

[96]  D. Sherrard,et al.  Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism. , 1978, The Journal of clinical endocrinology and metabolism.

[97]  F. Frey,et al.  Selective deficiency of hepatic triglyceride lipase in uremic patients. , 1977, The New England journal of medicine.